Cantargia: Phase I safety evaluation part of CANFOUR trial of antibody CAN04 completed and phase IIa part being initiated
Sunday, 09 December 2018
Fri, Dec 07, 2018 15:30 CET Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial. No dose limiting toxicities (DLTs) were reported at the highest dose level investigated, 10 mg/kg. According to the study protocol, the
- Published in Health & life sciences
No Comments